Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
tirzepatide for research purposes Peptide FDA Panel to Revisit Quantity:One Month Subscription inventory:985
FDA Panel to Revisit Biden Peptide Ban as It Weighs Looser Rules
Eli Lilly and Co Stock (LLY) Moved Up by 3.37% on Jun 8: What Signal Does It Send
inventory:985
Quantity:One Month Subscription
Products Description Tirzepatide 2023788-19-2 stands as the world's first "dual-target" agonist capable of simultaneously activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, thereby enabling more effective regulation of appetite and insulin secretion
US$ 22.88
US$ 20.94
US$ 24.77
US$ 23.81
US$ 27.01
US$ 24.68
US$ 22.56
US$ 22.71
US$ 25.42
US$ 23.71
US$ 29.48
US$ 29.11
